6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Xavier Pivot, Gilles Romieu, Marc Debled, Jean‐Yves Pierga et autres
us, fr (code pays fourni par la source)
129 citations
The Lancet